Are Empagliflozin and Dapagliflozin the same drug class?

Yes — both belong to ATC class A10B, meaning similar pharmacological action. Differences are in dose, formulation, and side-effect profile.

Can I switch from Empagliflozin to Dapagliflozin?

Switching between drugs requires medical supervision. Even within the same therapeutic class, dose conversions, washout periods, and overlap protocols must be followed to avoid efficacy loss or adverse events. Always consult your prescribing physician.

Does Empagliflozin or Dapagliflozin have more side effects?

Side-effect profiles differ between drugs. Both Empagliflozin and Dapagliflozin have documented adverse-effect lists in their official prescribing information. Compare the side effects sections on each individual drug page for the full breakdown.

Empagliflozin vs Dapagliflozin

Q: What is the difference between Empagliflozin and Dapagliflozin?

Empagliflozin (INN: EMPAGLIFLOZIN, ATC A10BK03) and Dapagliflozin (INN: DAPAGLIFLOZIN, ATC A10BK01) differ in active substance, indications, and safety profile. See the side-by-side table below for dosage, contraindications, and side effects.

Q: Can I take Empagliflozin and Dapagliflozin together?

Combination safety depends on both drugs' mechanisms and your health profile. Check interactions in our database and always consult your doctor or pharmacist before combining.

Q: Which is safer, Empagliflozin or Dapagliflozin?

Safety is patient-specific — both drugs are approved by regulatory authorities when used per label. The better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.

Description, Dosage, Side Effects, Contraindications. Data from EMA, URPL, openFDA and other regulatory sources.

	Empagliflozin	Dapagliflozin
Active Substances	EMPAGLIFLOZIN	DAPAGLIFLOZIN
ATC Code	A10BK03	A10BK01
Form	TABLET, FILM COATED	TABLET
Dosage	10 mg/1	10MG
Route	ORAL	ORAL
Manufacturer	A-S Medication Solutions	INVENTIA HEALTHCARE LTD
Indications	( ARTG ) Type 2 diabetes mellitus Glycaemic control JARDIANCE is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: Monotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy In combination with other glucoselowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see Section 5.1 Pharmacodynamic properties - Clinical trials). Prevention of cardiovascular death JARDIANCE is indicated in adult patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Section 5.1 Pharmacodynamic properties - Clinical trials). To prevent cardiovascular deaths, JARDIANCE should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care. Heart failure JARDIANCE is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see Section 5.1 Pharmacodynamic properties - Clinical trials). Chronic kidney disease JARDIANCE is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (CKD Stages 2 and 3A with urine ACR [greater than or equal to] 30 mg/g, or CKD Stages 3B, 4 and 5 irrespective of urine ACR).	Dapagliflozin is a sodium - glucose cotransporter 2 inhibitor (SGLT2) which is prescribed to lower the blood sugar levels in patients with type 2 diabetes. Dapagliflozin is usually given along with diet and exercise. The drug mainly acts by causing the kidneys to get rid of glucose in the urine.
Side Effects	This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme	General: Weakness, feeling tired. Gastrointestinal: Nausea, vomiting, pain in the stomach. Urinary System: Frequent urination which may result in dehydration and low blood pressure; urinary and genital fungal infection or other urinary tract infections resulting in symptoms of burning sensation while urinating, vaginal discharge in women, cloudy urine or penis discharge in men; and reduced kidney function which can cause bone fractures. Allergic reactions: Rash, hives, itching of the skin, breathing difficulties, swelling of the face, lips, mouth or the tongue. Blood: Low blood sugar levels, increase in cholesterol levels.
Warnings	—	• Dapagliflozin may cause serious kidney problems, therefore monitor kidney functions while taking the drug. • • Consult the doctor before having any surgery, even a dental surgery, while taking medicine. • • Get up slowly from the lying position; dapagliflozin may cause low blood pressure resulting in dizziness, lightheadedness or fainting. • • Dapagliflozin interacts with the urine glucose test. A urine glucose test is often carried out to measure the quantity of glucose present in the urine sample of diabetes patients. The urine may test positive for glucose if the patient is taking dapagliflozin even if glucose is absent. Therefore, alternative methods have to be followed to test sugar levels in patients taking dapagliflozin.

FAQ

What is the difference between Empagliflozin and Dapagliflozin?

Empagliflozin (INN: EMPAGLIFLOZIN, ATC A10BK03) and Dapagliflozin (INN: DAPAGLIFLOZIN, ATC A10BK01) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.

Can I take Empagliflozin and Dapagliflozin together?

Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.

Which is safer, Empagliflozin or Dapagliflozin?

Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

PillsCard

Almost ready…

Loading the latest data0%